Higher circulating ANGPTL8 levels in the early stages of NAFLD, which tend to decrease as the disease progresses. Serum ANGPTL8 levels were 271.0 ± 449.3 pg/mL in NAFLD patients (non-NASH and NASH group combined) and 93.22 ± 55.35 pg/mL in controls. Serum ANGPTL8 levels were statistically different (p = 0.05) when the controls and the two NAFLD groups (non-NASH and NASH) were compared, with significant differences lying between the control and non-NASH group (p = 0.02). This evidence concerns the gene ANGPTL8 and metabolic dysfunction-associated steatotic liver disease.